Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

AcnePsoriasis

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

J Eur Acad Dermatol Venereol

Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB, BADBIR Study Group

doi: 10.1111/jdv.20739

Psoriatic Arthritis

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Br J Dermatol

Graier T, Bordag N, Weger W, Laschober N, Ratzinger G, Jonak C, Prillinger K, Müllegger R, Mlynek A, Lange-Asschenfeldt B, Häring N, Hoetzenecker W, Posch C, Ellersdorfer C, Sator P, Gruber B, Hofer A, Gruber-Wackernagel A, Legat FJ, Großschädl K, Gruber V, Schadelbauer E, Repelnig M, Gressenberger P, Widnig A, Falkensteiner K, Salmhofer W, Wolf P

doi: 10.1093/bjd/ljaf394

Systemic Sclerosis

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

J Autoimmun

Chaigne B, Bense A, Aubourg F, Agard C, Allanore Y, Berezne A, Pugnet G, Hachulla E, Cottin V, Hot A, Dunogue B, Kanagaratnam A, Palat S, Lescoat A, Berthier S, Chatelus E, Rivière S, Launay D, Truchetet ME, Dinh-Xuan AT, Mouthon L, French Systemic Sclerosis Network

doi: 10.1016/j.jaut.2025.103391

Psoriasis

Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol

Alabas OA, Mason KJ, Yiu ZZN, Smith CH, Warren RB, Grifﬁths CEM, BADBIR study group

doi: 10.1093/bjd/ljaf017

Psoriasis

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

Acta Derm Venereol

Sieborg J, Maul JT, Wu JJ, Loft NN, Skov L, Bryld LE, Rasmussen MK, Dam TN, Bertelsen T, Ajgeiy KK, Thomsen SF, Thyssen JP, Egeberg A, Thein D

doi: 10.2340/actadv.v105.42572

Systemic Lupus Erythematosus

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Arthritis Res Ther

Kojima K, Ichinose K, Umeda M, Shimizu T, Sato S, Suzuki T, Nakashima Y, Okada A, Horai Y, Fujikawa K, Aramaki T, Miyashita T, Furuyama M, Matsuoka N, Kawakami A

doi: 10.1186/s13075-025-03581-0

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Psoriasis

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

J Am Acad Dermatol

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T

doi: 10.1016/j.jaad.2025.11.033

Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

J Eur Acad Dermatol Venereol

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K

doi: 10.1111/jdv.70155

Related content

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results